These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8730423)

  • 41. Abnormalities of erythrocyte sodium transport systems in Bartter's syndrome.
    Sechi LA; Melis A; Bartoli E
    Am J Nephrol; 1992; 12(3):137-43. PubMed ID: 1329511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence that circulating 6keto prostaglandin E1 causes the platelet defect of Bartter's syndrome.
    Clive DM; Stoff JS; Cardi M; MacIntyre DE; Brown RS; Salzman EW
    Prostaglandins Leukot Essent Fatty Acids; 1990 Dec; 41(4):251-8. PubMed ID: 2077538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bartter's and Gitelman's syndromes: from gene to clinic.
    Naesens M; Steels P; Verberckmoes R; Vanrenterghem Y; Kuypers D
    Nephron Physiol; 2004; 96(3):p65-78. PubMed ID: 15056980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Miscellaneous non-inflammatory musculoskeletal conditions. Bartter's and Gitelman's diseases.
    Favero M; Calò LA; Schiavon F; Punzi L
    Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):637-48. PubMed ID: 22142744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: role in activation of reduced nicotinamide adenine dinucleotide oxidase.
    Rane MJ; Carrithers SL; Arthur JM; Klein JB; McLeish KR
    J Immunol; 1997 Nov; 159(10):5070-8. PubMed ID: 9366435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low urinary calcium excretion in Bartter's syndrome.
    Rudin A; Aurell M; Wilske J
    Scand J Urol Nephrol; 1988; 22(1):35-9. PubMed ID: 3387909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis.
    Gwinn MR; Sharma A; De Nardin E
    J Periodontol; 1999 Oct; 70(10):1194-201. PubMed ID: 10534074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blood and extracellular fluid volume in patients with Bartter's syndrome.
    Boer P; Hené RJ; Koomans HA; Nieuwenhuis MG; Geyskes GG; Mees EJ
    Arch Intern Med; 1983 Oct; 143(10):1902-5. PubMed ID: 6625776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin II type 1 receptor gene abnormality in a patient with Bartter's syndrome.
    Yoshida H; Kakuchi J; Yoshikawa N; Saruta T; Inagami T; Phillips JA; Ichikawa I
    Kidney Int; 1994 Dec; 46(6):1505-9. PubMed ID: 7699991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impaired D-myo-inositol 1,4,5-triphosphate generation from cord blood polymorphonuclear leukocytes.
    Santoro P; Agosti V; Viggiano D; Palumbo A; Sarno T; Ciccimarra F
    Pediatr Res; 1995 Oct; 38(4):564-7. PubMed ID: 8559610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Development of tetany in siblings suffered from Bartter's syndrome].
    Suitsu N; Kita S; Okamoto S; Kimura S; Shiozaki Y
    No To Shinkei; 1984 Aug; 36(8):749-54. PubMed ID: 6498022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation.
    Wenzel-Seifert K; Grünbaum L; Seifert R
    J Immunol; 1991 Sep; 147(6):1940-6. PubMed ID: 1653806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neo-Mull-Soy metabolic alkalosis: a model of Bartter's syndrome?
    Reznik VM; Griswold WR; Mendoza SA; McNeal RM
    Pediatrics; 1980 Nov; 66(5):784-6. PubMed ID: 7432885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Granulocytes from chronic myeloid leukemia (CML) patients show differential response to different chemoattractants.
    Radhika V; Thennarasu S; Naik NR; Kumar A; Advani SH; Bhisey AN
    Am J Hematol; 1996 Jul; 52(3):155-64. PubMed ID: 8756080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. (2R,3R)-2-(3',4'-dihydroxybenzyl)-3-(3'',4''-dimethoxybenzyl)butyrolactone suppresses fMLP-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils.
    Huang YJ; Chen IS; Tseng CP; Day YJ; Lin YC; Liao CH
    Biochem Pharmacol; 2008 Feb; 75(3):688-97. PubMed ID: 17988652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pregnancy complicated with Bartter's syndrome: a case report.
    Nohira T; Nakada T; Akutagawa O; Fujito A; Okabe K; Ioya N; Yoshida M
    J Obstet Gynaecol Res; 2001 Oct; 27(5):267-74. PubMed ID: 11776509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. fMLP receptor stimulated activation of macrophage: its effect on killing of intracellular Leishmania donovani.
    Dasgupta D; Chakraborty P; Basu MK
    Biosci Rep; 2000 Oct; 20(5):345-54. PubMed ID: 11332597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endothelin and vascular reactivity in Bartter's syndrome.
    Calò L; Cantaro S; Rizzolo M; Favaro S; Antonello A; Borsatti A
    Nephron; 1994; 66(3):370-1. PubMed ID: 8190199
    [No Abstract]   [Full Text] [Related]  

  • 59. Evidence of myocardial dysfunction in Bartter's syndrome.
    Calò L; Scognamiglio R; Nistri S; Palisi M; Miorelli M; Zerbo F; Cantaro S; Antonello A; Fasoli G; D'Angelo A
    Am J Nephrol; 1997; 17(2):124-7. PubMed ID: 9096442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bartter's syndrome: a disorder of vascular reactivity. Arthur C. Corcoran Memorial Lecture.
    Bartter FC
    Hypertension; 1981; 3(3 Pt 2):I69-73. PubMed ID: 7262981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.